ReproCell Stock

ReproCell Current Liabilities

The Current Liabilities of ReproCell (4978.T) as of Sep 4, 2026 is 640.59 M JPY. In the previous year, Current Liabilities was 678.40 M JPY — a change of -5.57% (lower).

Current Liabilities

640.59 MJPY

YoY

-5.57%

Last updated:

Current Liabilities of ReproCell is 2026 640.59 M JPY. Current Liabilities of ReproCell was 2025 678.40 M JPY. It decreases by -5.57% lower compared to the previous year.

The ReproCell Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2018
261.02 M JPY
Jan 1, 2019
330.42 M JPY
Jan 1, 2020
406.94 M JPY
Jan 1, 2021
553.43 M JPY
Jan 1, 2022
827.26 M JPY
Jan 1, 2023
749.66 M JPY
Jan 1, 2024
678.40 M JPY
Jan 1, 2025
640.59 M JPY
The ReproCell Current Liabilities history
YEARCurrent LiabilitiesYoY
640.59 MJPY-5.57%
678.40 MJPY-9.51%
749.66 MJPY-9.38%
827.26 MJPY+49.48%
553.43 MJPY+36.00%
406.94 MJPY+23.16%
330.42 MJPY+26.59%
261.02 MJPY-7.40%
281.89 MJPY-38.23%
456.33 MJPY+52.50%
299.24 MJPY+120.84%
135.50 MJPY+104.37%
66.30 MJPY+8.69%
61.00 MJPY+35.86%
44.90 MJPY-14.48%
52.50 MJPY+67.20%
31.40 MJPY+46.05%
21.50 MJPY
Access this data via the Eulerpool API

ReproCell Stock analysis

What does ReproCell do? ReproCell, Inc. is a company that was founded in 2003 and specializes in the research and manufacture of cell cultures. The company is based in Yokohama, Japan and operates worldwide. Its business model includes providing services and products to support research and development activities in the field of regenerative medicine and cell therapy. The company is divided into three main divisions: the Biorepository Division, which provides human cells and tissues for research purposes; the Cell Manufacturing Division, which develops production processes for cell therapy products; and the Drug Discovery Division, which supports drug development through screening and in vitro testing. ReproCell offers a variety of cell cultures, including stem cells from various sources, as well as related media, reagents, and tools for cultivation and application. In addition, the company offers services in cell therapy production, working closely with customers to provide customized and high-quality therapies. ReproCell also supports drug and compound research through screening and in vitro testing, with various platforms available for the identification and evaluation of new compounds. The company has a history of growth and has become a leading player in the field of cell culture and cell therapy production. In conclusion, ReproCell plays a significant role in regenerative medicine and cell therapy production, offering a wide range of products and services to support research and development in these areas. It is poised to continue its growth and contribute to the development of new therapies in the future. ReproCell is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ReproCell stock

Current Liabilities of ReproCell is 640.59 M JPY in 2026.

Current Liabilities of ReproCell changed from 678.40 M JPY to 640.59 M JPY, representing a -5.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities ReproCell since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's ReproCell historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ReproCell

All Key Metrics — ReproCell